期刊文献+

曲古抑菌素A对博莱霉素致肺纤维化小鼠新生血管的影响 被引量:1

Effect of trichostatin A on lung angiogenesis in mice with bleomycin-induced pulmonary fibrosis
下载PDF
导出
摘要 目的探讨组蛋白脱乙酰基转移酶抑制剂曲古抑菌素A(trichostatinA,TSA)对博莱霉素诱导肺纤维化小鼠的新生血管的影响。方法120只雄性C57BL/6小鼠随机分为控制对照组(CG)、肺纤维化模型组(MG)、TSA早期处理组(EG)和TSA晚期处理组(LG)。MG、EG、LG予以博莱霉素溶液10mg/kg气管内注射建立小鼠肺纤维化模型,CG予以等体积019%氯化钠溶液注射。TSA处理组在造模后分两个阶段(早期:第1~14天;晚期:第15~28天)予以TSA溶液40mg/kg腹腔内注射,每周2次;CG和MG则予以等体积二甲基亚砜(Dmso)腹腔注射。各组于造模后第7、14、28天分三批处死,观察肺组织大体,行HE和Masson染色,Szapiel评分,测定羟脯氨酸(HYP)含量,免疫组化检测血管内皮生长因子(vascularendothelialgrothfactor,VEGFo结果小鼠造模均成功:CG小鼠未见蓝色胶原沉积;MG小鼠可见蓝色胶原沉积明显;并随着小鼠生存时间延长,蓝色胶原沉积加重,EG小鼠可见蓝色胶原沉积介于CG组与MG组之间;LG组蓝色胶原沉积较EG更重。与CG组比较,其他各组各时点HYP含量及VEGF的tOD值均发生显著变化(均P〈0.01);与MG组比较,EG组第7、14、28天HYP含量均显著降低(均P〈001);与EG组比较.LG组第7、14、28天HYP含量均显著升高(均P〈0.01)与MG组比较,EG组第7、14、28天VEGF的IOD值均发生显著变化(均P〈001);与EG组比较,LG组第7、14、28天VEGF的IOD值均显著升高(均P〈0.01o结论早期予以TSA可以抑制博莱霉素致肺纤维化小鼠新生血管形成,减轻肺问质纤维化,晚期干预则没有明显作用。 Objective TO investigate the effects of histone deacetylase inhibitor (HDACI)trichostatin A (TSA) on lung an- giogenesis in mice with bleomycin-induced pulmonary fibrosis. Methods One hundred and twenty C57BL/6 mice were ran- domly divided into four groups(n=30 in each group). Pulmonary fibrosis was induced by intratracheal injection of bleomycin 10mg in MG, EG and LG groups. Intraparitoneal injection of TSA was given 2/w to mice in EG ((:11-d14) and LG (d15-28) groups; and same volume of dimethyl sulfoxide (DMSO) was given to mice in CG and MG groups. Mice were sacrificed in batches at d7, 14 and 28, the lung tissue specimens were stained with HE and Masson method and the fibrosis was evaluated with Szapiel score. The hydroxyproline (HYP) level was measured and VEGF was detected by immunohistochemistry. Results The HYP contents and the expression of VEGF in MG and LG were significant higher than those in CG; while the HYP level and the VEGF expression in EG were lower than those in MG and LG. Conclusion Results indicate that early administration of TSA in mice with bleomycin induction can attenuate the pulmonary fibrosis via inhibiting angiogenesis, however, delayed administration of TSA has no signifi- cant effect.
出处 《浙江医学》 CAS 2014年第5期370-373,共4页 Zhejiang Medical Journal
基金 杭州市卫生科技计划A类项目(2011A017)
关键词 组蛋白脱乙酰基转移酶抑制剂肺间质纤维化新生血管 Histone deacetylase inhibitor(HDACI) Pulmonary interstitial fibrosis Angiogenesis
  • 相关文献

参考文献16

  • 1American Thoracic Society (ATS), and the European RespiratorySociety (ERS). Idiopathic pulmonary fibrosis: diagnosis andtreatment,International consensus statementfJ]. Am J Respir CritCare Med.2000,161:646-664.
  • 2Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine recep-tor-2 (CCR2) deficiency improves bleomycin-induced pul-monary fibrosis by attenuation of both macrophage infiltrationand production of macrophage-derived matrix metallopro-teinases[J].J Pathol, 2004, 204: 594-604.
  • 3Chen H W, Lacombe L, Montgomery K, et a!. HATs on and be-yond ChromatinfJ]. Current opinion in cell biology Opinion in Cell巳 iology,2001,13:218.
  • 4Ferrara N. Vascular endothelial growth factor[J]. Trends Cardio-vasc Med,1993,3:244-250.
  • 5Kim M S, Kwon H J, Lee Y M,et al. Histone deacetylases inducean- giogenesis by negative regulation of tumor suppressorgenes[J].Nat Med,2001,7:437-443.
  • 6Deroanne C F, Bonjean K, Servotte S,et al.Histone deacetylasesinhibitors as anti-angiogenic agents altering vascular endothelialgrowth factor signaling[J].Oncogene,2002,21,427-436.
  • 7Maheshwari U, Gupta D, Aggarwal A N, et al. Spectrum and di-agnosis of idiopathic pulmonary fibrosis[J].Indian J Chest Dis Al-lied Sci,2004,46:23-26.
  • 8Szapiel S V.EIson N A,Fulmer J D. Bleomycin-induced interstitialpulmonary disease in the nude athymic mouse[J].Am Rev RespirDis,1979,120:893-899.
  • 9Kook H.Lepore J J,Gitler A D,et al.Cardiac hypertrophy and hi-stone deacetylase-dependent transcriptional repression medi-ated by the atypical homeodomain protein Hop[J].J Clin Invest,2003,112:863-871.
  • 10Kouzarides T.Histone acetylase and deacetylase in cell prolif-eration[J]. Curr Opin Genet Devt1999,9(1):40-48.

同被引文献16

  • 1Behr L.The diagnosis and treatment of idiopathic pulmonaryfibrosis[J]. Dtsch Arztebl Int, 2013,110(51-52):875-881.
  • 2Ahluwalia N, Shea B S, Tager A M, et al. New therapeutic targets inidiopathic pulmonary fibrosis. Aiming to rein in runawaywoundhealing responses[J]. Am J Respir Crit Care Med, 2014,190(8):867-878.
  • 3Kalayarasan S, Sriram N, Soumyakrishnan S, et al. Dially丨sulfideattenuates excessive collagen production and apoptosis in a ratmodel of bleomycin induced pulmonary Fibrosis through theinvolvement of protease activated receptor-2[J]. Toxicol ApplPharmacol,2013,271(2): 184-195.
  • 4Usuki J, Matsuda K, Azuma A, et al. Sequential analysis ofmyofibroblast differentiation and transforming growth factor- p 1/Smad pathway activation in murine pulmonary fibrosis[J], NipponMed Sch(2012,79(1 ):46-59.
  • 5Deroanne C F, Bonjean K, Servotte S, et al. Histone deacetylasesinhibitors as anti-angiogenic agents altering vascular endothelialgrowth factor signaling[J], Oncogene, 2002,21(3):427-436.
  • 6Maheshwari U, Gupta D, Aggarwal A N, et al. Spectrum anddiagnosis of idiopathic pulmonary fibrosis[J], Indian J Chest DisAllied Sci, 2004,46(1):23-26.
  • 7Szaptei S V, Elson N A, Fulmer J D, et al. Bleomyeinduce interstitialpulmonaty disease in the nude, athymic mouse[J], Am Rev RespirDis, 1979,120(4):893-899.
  • 8Hamid T, Guo S Z, Kingery J R, et at. Cardiomyocyte NF-KB p65promotes adverse remodeling,apoptosis, and endoplasmicreticulum stress in heart failure[J]. Cardiovasc Res, 2011, 89(1):129-138.
  • 9Rahman M M, Kukita A, Kukita T, et al. Two histone deacetylaseinhibitors, trichostatin A and sodium butyrate, suppressdifferentiation into osteoclasts but not into macrophages [J].Blood, 2003, 101(9):3451-3459.
  • 10Parekh D, Dancer R C, Thickett D R, Acute lung injury[J]. Clin Med(Lond), 2011,11(6):615-618.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部